What Is Mast Cell Activation Syndrome?
Mast Cell Activation Syndrome (MCAS) is a chronic, multi-system disorder in which mast cells — immune cells found throughout the body — activate inappropriately and release excessive amounts of inflammatory mediators. The result is a bewildering array of symptoms affecting virtually every organ system, often with no clear trigger and no abnormal findings on standard laboratory testing.
MCAS is frequently misdiagnosed as anxiety, fibromyalgia, IBS, or hypochondria. In reality, it is a genuine immunological disorder that is increasingly recognized as a root cause of chronic illness, particularly in patients with Ehlers-Danlos syndrome (EDS), POTS, and post-infectious conditions including Long COVID.
Understanding Mast Cells
Mast cells are tissue-resident immune cells derived from bone marrow progenitors. They are found in highest concentrations at the body's interfaces with the external environment — the skin, gut lining, respiratory tract, and blood vessel walls. Their primary role is to serve as first responders to pathogens, allergens, and tissue injury.
When activated, mast cells degranulate — releasing preformed mediators stored in granules (histamine, heparin, tryptase, chymase) and synthesizing new mediators (prostaglandins, leukotrienes, cytokines, chemokines). In MCAS, this degranulation occurs excessively and inappropriately, flooding tissues with inflammatory compounds.
Symptoms of MCAS
MCAS symptoms are notoriously variable and can affect any organ system. Common presentations include:
- Skin: Flushing, hives (urticaria), dermatographism, itching, rashes
- Gastrointestinal: Nausea, vomiting, diarrhea, abdominal cramping, bloating, reflux
- Cardiovascular: Palpitations, low blood pressure, fainting (often overlapping with POTS)
- Neurological: Brain fog, headaches, anxiety, sensory hypersensitivity
- Respiratory: Wheezing, shortness of breath, chronic cough, nasal congestion
- Musculoskeletal: Joint pain, muscle aches, fatigue
- Systemic: Anaphylactoid reactions, temperature dysregulation, chemical sensitivities
A hallmark of MCAS is reactivity to multiple seemingly unrelated triggers — foods, fragrances, medications, temperature changes, stress, exercise, and infections. Patients often describe feeling like they are allergic to everything.
Root Causes and Triggers of MCAS
MCAS rarely occurs in isolation. Common underlying drivers include:
- Chronic infections: Lyme disease, EBV reactivation, mold illness (CIRS), and SIBO are among the most common infectious triggers
- Connective tissue disorders: Hypermobile EDS creates structural instability that chronically activates mast cells
- Gut dysbiosis and leaky gut: Dysbiotic bacteria produce histamine and other mast cell activators; intestinal permeability allows these compounds to enter systemic circulation
- Toxic exposures: Mold mycotoxins, heavy metals, and pesticides directly activate mast cells
- Autonomic dysfunction: POTS and dysautonomia create a chronic stress state that primes mast cells for activation
- Post-infectious: Long COVID is now recognized as a major trigger of new-onset MCAS
Diagnosis
MCAS diagnosis requires clinical criteria plus laboratory evidence of mast cell mediator release. Key tests include:
- Serum tryptase: Elevated during acute reactions; a baseline above 11.4 ng/mL is suggestive
- 24-hour urine histamine and metabolites: N-methylhistamine, prostaglandin D2 metabolites (11-beta-PGF2alpha), leukotriene E4
- Plasma histamine: Useful during acute reactions
- Chromogranin A: Elevated in systemic mast cell disease
- Bone marrow biopsy: Required to rule out systemic mastocytosis (a more severe mast cell disorder)
Testing must be performed during or shortly after a symptomatic episode for accurate results. Many patients require multiple tests before abnormalities are captured.
The MCAS Protocol: A Layered Approach
Effective MCAS management requires a layered protocol addressing mediator blockade, trigger avoidance, mast cell stabilization, and root cause treatment simultaneously.
Layer 1: Mediator Blockade
H1 antihistamines: The foundation of MCAS symptom management. Non-sedating options (cetirizine, loratadine, fexofenadine) are preferred for daytime use; hydroxyzine or diphenhydramine may be used at night. Many MCAS patients require higher-than-standard doses — work with a physician to optimize.
H2 antihistamines: Famotidine (Pepcid) blocks histamine receptors in the gut and complements H1 blockade. Particularly useful for GI symptoms.
Leukotriene inhibitors: Montelukast (Singulair) blocks leukotriene receptors, reducing respiratory and inflammatory symptoms driven by leukotriene release.
Aspirin (low-dose): Blocks prostaglandin synthesis. Useful for flushing and cardiovascular symptoms driven by prostaglandin D2. Must be introduced carefully as some MCAS patients are aspirin-sensitive.
Layer 2: Natural Mast Cell Stabilizers
Quercetin: A flavonoid with potent mast cell-stabilizing properties. Quercetin inhibits IgE-mediated degranulation and reduces histamine release. Dose: 500–1000mg twice daily with meals. Bromelain enhances absorption.
Luteolin: Another flavonoid with strong mast cell-stabilizing and anti-neuroinflammatory effects. Particularly useful for neurological MCAS symptoms and brain fog.
Vitamin C: Degrades histamine enzymatically and supports DAO (diamine oxidase) enzyme activity. Liposomal or buffered forms are better tolerated. Dose: 1–3g daily.
DAO enzyme supplementation: Diamine oxidase is the primary enzyme responsible for degrading dietary histamine in the gut. DAO deficiency is common in MCAS. Supplementing DAO before meals reduces histamine load from food.
Palmitoylethanolamide (PEA): An endogenous lipid mediator that downregulates mast cell activation. Particularly effective for pain and neurological symptoms. Dose: 600–1200mg daily.
Cromolyn sodium: A prescription mast cell stabilizer available as oral solution, nasal spray, or inhaler. Particularly effective for GI MCAS symptoms.
Layer 3: Low-Histamine Diet
During active MCAS flares, a low-histamine diet reduces the total histamine burden and decreases mast cell activation. Foods to avoid include:
- Fermented foods (sauerkraut, kimchi, kefir, kombucha, aged cheeses, wine, beer)
- Cured and processed meats (salami, pepperoni, bacon)
- Leftover foods (histamine increases as food ages)
- Shellfish and certain fish (tuna, mackerel, sardines)
- Tomatoes, spinach, eggplant, avocado
- Alcohol (especially red wine)
- Vinegar and vinegar-containing foods
Fresh, single-ingredient foods prepared and eaten immediately are best tolerated. The low-histamine diet is a temporary tool — not a permanent lifestyle — used to reduce symptom burden while root causes are addressed.
Layer 4: Root Cause Treatment
Symptom management without root cause treatment leads to ongoing MCAS. Key root cause interventions include:
- Treat underlying infections: Address Lyme, EBV, SIBO, and mold illness with appropriate antimicrobial, antiviral, or binder protocols
- Heal the gut: Restore intestinal barrier integrity with L-glutamine, zinc carnosine, colostrum, and butyrate to reduce histamine-producing dysbiosis
- Address mold exposure: Remove from moldy environment; use binders (cholestyramine, activated charcoal, bentonite clay) to clear mycotoxins
- Support autonomic nervous system: Vagal nerve stimulation, breathwork, cold therapy, and POTS management reduce the chronic stress state that primes mast cells
- Optimize vitamin D: Vitamin D is a potent immune modulator that reduces mast cell reactivity. Target serum levels of 60–80 ng/mL
Tracking and Pacing
MCAS management requires careful tracking of symptoms, triggers, and responses to interventions. A symptom diary identifying food, environmental, emotional, and activity triggers is invaluable. Many patients find that their trigger threshold changes over time — as root causes are addressed, tolerance improves and the trigger list shrinks.
Pacing is essential during flares. Overexertion — physical or cognitive — is a common MCAS trigger. The goal is to stay below the activation threshold while systematically reducing that threshold through root cause treatment.
The Path Forward
MCAS is complex but treatable. With a systematic layered approach — mediator blockade, mast cell stabilization, trigger avoidance, and root cause treatment — most patients experience meaningful improvement. The key is patience, precision, and working with a practitioner experienced in mast cell disorders.
0 comments